Back

Sudden cardiac death risk stratification using contemporary international guidelines and genetic findings in hypertrophic cardiomyopathy

20 May 2023 (16:25 - 16:34)
Organised by: Logo
Congress Presentation Part of: Arrythmias and device therapy in chronic heart failure Hypertrophic Cardiomyopathy Open Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jan Koelemen

University Hospital Heidelberg, Heidelberg (Germany)

6 More presentations in this session

Presentation thumbnail
Early rhythm control in patients with atrial fibrillation and heart failure: association with long-term outcome in a large european cohort
Doctor N. Bonini (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Multimodality imaging assessment of mitral annulus disjunction in consecutive patients and its clinical impact
Doctor M. Lo Monaco (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Epicardial adipose tissue accumulation is associated with malignant ventricular arrhythmias in phospholamban cardiomyopathy
Mr B. Mahmoud (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Clinical impact of remote heart failure management using a multiparametric implantable cardioverter-defibrillator alert: the multicentric Spanish RE-HEART Registry
Doctor J. De Juan Baguda (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
The effect of atrial pacing in cardiac resynchronization therapy
Doctor E. Zsigmond (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Arrythmias and device therapy in chronic heart failure
Video

The Event

Event poster

Heart Failure 2023

20 May 2023 16:25 CET
You may be interested in
thumbnail
Congress Presentation
Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
The challenge of risk stratification in hypertrophic cardiomyopathy: clinical, genetic and imaging insights from a quaternary referral centre
thumbnail
Congress Presentation
'The overlooked middle': patient with non-ischaemic cardiomyopathy and moderately impaired ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources